Inactivating Tp53 mutations are frequent genetic lesions in human tumors that harbor genomic instability, including B lineage lymphomas with IG translocations. Antigen receptor genes are assembled and modified in developing lymphocytes by RAG/AID-initiated genomic rearrangements that involve the induction of DNA double strand breaks (DSBs). Although TP53 inhibits the persistence of DSBs and induces apoptosis to protect cells from genomic instability and transformation, the development of spontaneous tumors harboring clonal translocations has not been reported in mice that only lack wild-type Tp53 protein or express Tp53 mutants. Tp53-deficient (Tp53 À/À ) mice succumb to T lineage lymphomas lacking clonal translocations but develop B lymphoid tumors containing immunoglobulin (Ig) translocations upon combined inactivation of DSB repair factors, RAG mutation or AID overexpression; mice expressing apoptosis-defective Tp53 mutants develop B cell lymphomas that have not been characterized for potential genomic instability. As somatic rather than germline inactivating mutations of TP53 are typically associated with human cancers and Tp53 deletion has cellular context dependent effects upon lymphocyte transformation, we generated mice with conditional Tp53 deletion in lineage-committed B lymphocytes to avoid complications associated with defective Tp53 responses during embryogenesis and/or in multilineage potential cells and, thereby, directly evaluate the potential physiological role of Tp53 in suppressing translocations in differentiated cells. These mb1-cre:Tp53 flox/flox mice succumbed to lymphoid tumors containing Ig gene rearrangements and immunophenotypes characteristic of B cells from various developmental stages. Most mb1-cre: Tp53 flox/flox tumors harbored clonal translocations, including Igh/c-myc or other oncogenic translocations generated by the aberrant repair of RAG/AID-generated DSBs.
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Introduction
The diversity of antigen receptors expressed on the surface of B and T cells enables adaptive immune systems to recognize and respond to an enormous variety of pathogens. Antigen-recognition diversity is established in developing lymphocytes through the assembly of immunoglobulin (Ig) and T-cell receptor (TCR) genes from germline variable (V), diversity (D) and joining (J) gene segments (Soulas-Sprauel et al., 2007) . V(D)J recombination is initiated by the RAG endonuclease, which cleaves Ig/TCR loci adjacent to gene segments in G1 phase cells, and completed by nonhomologous end-joining (NHEJ) and DNA damage response proteins, which process and join RAGgenerated DNA ends. The combination of joining events and the imprecise processing of V(D)J ends generates a vast repertoire of antigen receptor genes. During immune responses, Ig genes are diversified further in mature B cells through class switch recombination (CSR) of Ig heavy-chain constant (C H ) region exons and somatic hypermutation (SHM) of IgH, Igk and Igl variable region exons (Soulas-Sprauel et al., 2007) . CSR is initiated by the AID protein, which deaminates cytosines and leads to double strand breaks (DSBs) within IgH switch (S) regions in G1 phase cells, and is completed by NHEJ and DNA damage response proteins, which join AID-liberated DNA ends. SHM also is initiated by AID, but does not involve DSB intermediates. CSR creates IgH chains with different effector functions and SHM selects for higher-affinity antibodies. Although V(D)J recombination and CSR are essential for adaptive immunity, these processes impose hazards upon lymphocytes and host organisms due to their obligate DSB intermediates.
The TP53 tumor suppressor protein responds to DSBs and other many other cellular stresses to activate cell cycle checkpoints, induce senescence or trigger apoptosis and, thereby, prevent cellular transformation (Vousden and Prives, 2009) . Upon G1 phase DSBs, TP53 functions to prevent G1/S transition until DNA breaks are repaired or trigger apoptosis if the damage is un-repairable (Vousden and Prives, 2009) . Somatic inactivation of TP53 is observed in human tumors containing genomic instability including B lineage lymphomas with clonal IG translocations generated through aberrant V(D)J recombination or CSR (Cheung et al., 2009) , indicating that TP53 may prevent genomic instability such as RAG/AID-initiated translocations from forming and/or driving transformation. Multiple independent observations in mice support these notions. First, Tp53 induces apoptosis of NHEJdeficient lymphocytes with un-repaired RAG DSBs and inhibits persistence of RAG DSBs outside of G1 phase in NHEJ-sufficient thymocytes Dujka et al., 2010) . Second, germline NHEJ/Tp53-deficient mice succumb to pro-B lymphomas with RAG-dependent Igh/c-myc or Igh/N-myc translocations (Difilippantonio et al., 2002; Zhu et al., 2002; Gladdy et al., 2003; Rooney et al., 2004) . Third, Tp53 À/À mice expressing a RAG1 mutant that exhibits defects in DNA end joining develop thymic lymphomas with clonal antigen receptor locus translocations (Giblin et al., 2009) . Fourth, Tp53 À/À mice containing a genetic block in thymocyte development succumb to thymic lymphomas with RAG-dependent genomic instability (Haines et al., 2006) . Fifth, Tp53 deficiency leads to or unmasks the oncogenic potential of RAG-dependent Igh/c-myc and Tcra/c-myc translocations and AID-initiated Igh/c-myc translocations in lymphocytes lacking histone H2AX Celeste et al., 2003a; Bassing et al., 2007) . Sixth, Tp53 suppresses the frequency of nonmalignant B cells with AID-initiated Igh/c-myc translocations (Ramiro et al., 2006; Santos et al., 2010) . Seventh, Tp53
À/À mice with inactivation of NHEJ in mature B cells succumb to tumors with oncogenic Igh/cmyc translocations arising through CSR errors, or clonal translocations involving aberrant Igk and Igl V(D)J recombination (Wang et al., 2008 (Wang et al., , 2009 ). Finally, Tp53 À/À mice with transgenic AID overexpression develop B cell lymphomas containing clonal miR142/ c-myc or Igh/c-myc translocations formed by 'off-target' AID activity (Robbiani et al., 2009) .
Despite the role of Tp53 in suppressing B lineage lymphomas with Ig translocations in cell populations experiencing elevated frequencies of RAG/AID-initiated DSB intermediates, Tp53 À/À mice succumb to thymic lymphomas that lack clonal translocations involving Tcr or other genomic loci and do not develop B lymphoid tumors (Liao et al., 1998; Bassing et al., 2003; Celeste et al., 2003a) . Mice expressing apoptosis-defective Tp53 mutants in all cells beginning in early embryos develop B lineage lymphomas (MacPherson et al., 2004; Slatter et al., 2009) ; however, whether these malignancies contain Ig translocations or other types of genomic instability was not reported. The cellular origin, developmental timing and molecular mechanism of oncogene activation and tumor suppressor gene inactivation can influence cancer predisposition and tumor phenotype. For example, wild-type and Rag1 À/À mice with C-MYC expression initiating in B and T lymphocyte lineages succumb at similar ages to B lymphoid tumors (Adams et al., 1985; Nepal et al., 2008) ; whereas, mice with C-MYC expression starting in hematopoietic stem cells develop T cell lymphomas, but succumb at later ages to both B and T lineage tumors when on a Rag1 À/À background (Smith et al., 2005) . In addition, mice with H2ax and Tp53 deletion initiating in lineage-committed T cells develop immature T-cell lymphomas more rapidly and of later developmental stages than germline H2ax À/À Tp53 À/À mice (Yin et al., 2010) . Accordingly, the mortality of Tp53 À/À mice from thymic lymphomas involving oncogenic lesions that arise during embryogenesis and/or in cells before lineage-commitment, might mask the role of Tp53 in suppressing B lymphoid tumors with Ig translocations formed by physiological levels of RAG/AID-initiated DSB intermediates. Thus, to directly evaluate the potential role of Tp53 in suppressing oncogenic translocations in differentiated cells, we generated and analyzed mice with conditional Tp53 deletion in lineage-committed B lymphocytes.
Results and discussion
The mb1-cre mouse provides an experimental approach to obtain deletion of 'floxed' genes in B lineage cells initiating at the early pro-B cell stage (Hobeika et al., 2006) . Thus, we generated and characterized a cohort of 14 mb1-cre:Tp53 flox/flox mice. We frequently observe mb1-cre-mediated deletion of 'floxed' genes in non-lymphoid cells when the transgene is inherited maternally, but not paternally. Consequently, to avoid complications associated with transgene activation in female germ cells and bi-allelic copies of the transgene, mb1-cre:Tp53 flox/flox mice were generated by breeding mb1-cre males with Tp53 flox/flox females (Jonkers et al., 2001; Hobeika et al., 2006) and their mb1-cre:Tp53 flox/wt male offspring with Tp53 flox/flox females. Cohort mb1-cre:Tp53 flox/flox mice survived tumor-free between 81-177 days with a median age of mortality at 128 days ( Figure 1a ). All mice developed malignancies that were either disseminated throughout peripheral lymphoid tissues or restricted to one or more lymph nodes (data not shown). mb1-cre:Tp53 flox/flox cohort mice did not develop other malignancies. In addition, no tumors arose in mb1-cre, mb1-cre:Tp53 flox/ þ or Tp53 flox/flox control mice aged over the same time. These data reveal that cre-mediated tumors and 129SvEv or C57BL6 kidneys, conducted as previously described Wu et al., 2003) . The position of the germline (GL) band is indicated. The images were cropped from a larger blot. (f-h) FACS analysis with anti-B220 and anti-CD43 antibodies (f), anti-IgM and anti-IgD antibodies (g) or anti-Igk and anti-Igl antibodies (h) on single cell suspensions of the indicated mb1-cre:Tp53 flox/flox lymphomas and wild-type (WT) lymph nodes, conducted as previously described .
deletion of Tp53 initiating in pro-B cells predisposes mice to spontaneous lymphoid malignancies. Mature B cells develop through a differentiation program that involves the developmental stage-specific assembly of Ig genes. To determine the developmental stage(s) from which mb1-cre:Tp53 flox/flox lymphomas arose, we analyzed potential Ig rearrangements in these tumors. Germline J H segments reside on a 6.0-kb EcoRI fragment (Figure 1b ) that changes size upon Igh rearrangements in pro-B cells. Southern blot analysis of EcoRI-digested DNA using a 3 0 J H probe revealed that most tumors contained non-germline J H loci (Figure 1c) . Notably, tumor #160 contained three non-germline sized fragments where the signal intensity of one was greater than the other two (Figure 1c ), analogous to Igh rearrangements in pro-B lymphomas of NHEJ/Tp53-deficient and H2AX/Tp53-deficient mice. These tumors harbor a t(12;15) translocation with 3 0 J H sequences and a t(15;12) translocation with amplified 3 0 J H sequences, which arise following replication of a chromosome 12 harboring un-repaired Igh DSBs, as well as a normal chromosome 12 with 3 0 J H sequences (Difilippantonio et al., 2000; Gao et al., 2000; Bassing et al., 2003; Celeste et al., 2003b) . Germline Jk segments reside on an 8.9-kb BamHI fragment (Figure 1d ) that changes size upon Vkto-Jk rearrangements or is deleted upon Vk rearrangements to the 3 0 Igk deleting element, each of which occurs in pre-B cells. Southern blotting of BamHIdigested DNA using a 3 0 Jk probe and then a loading control probe revealed that at least seven tumors contained non-germline or deleted Jk loci (Figure 1e ). In addition, at least four of the tumors with Igk rearrangements (#55, 29, 99, and 603) also harbored non-germline S regions (data not shown). These Southern data demonstrate that cre-mediated Tp53 deletion initiating in pro-B cells results in the malignant transformation of B lineage-committed cells at various developmental stages.
To further define the developmental stage(s) from which mb1-cre:Tp53 flox/flox lymphomas arose, we sought to determine their cell surface immunophenotype. FACS analysis of 11 mb1-cre:Tp53 flox/flox tumors revealed that all expressed B220, CD43 and CD19 (Figures 1f-h We next conducted spectral karyotyping of mb1-cre:Tp53 flox/flox B lymphoid tumors to assay for potential translocations. We analyzed metaphase spreads prepared from 11 lymphomas and found that nine contained at least one clonal translocation (Table 1) . Six of these tumors also contained one or more non-clonal translocation (Table 1) . Three B lineage lymphomas (#55, 99 and 603) contained clonal t(12;15) transloca- Table 1 ). Tumor #972 contained a similar non-clonal t(12;15) translocation ( Figure 2b and Table 1 ). Another tumor (#57) contained clonal t(16;9) and t(11;16) translocations ( Figure 2c and Table 1 (Table 1) ; these lesions could have developed from DSBs generated by 'off-target' RAG/AID activity and/ or other factors such as DNA replication errors. Consistent with the former notion, tumor #29 harbored a clonal t(11;15) translocation (Figure 2d and Table 1 ) similar to the AID-dependent translocations that fuse miR142 on chromosome 11 to the c-myc locus on chromosome 15 creating fusion genes that drive c-myc overexpression (Robbiani et al., 2009) . These spectral karyotyping data demonstrate that cre-mediated deletion of Tp53 in developing B cells leads to lymphomas with clonal and non-clonal translocations.
As a means to determine if the clonal translocations of particular mb1-cre:Tp53 flox/flox B lineage lymphomas might have arisen through the aberrant repair of RAG/ AID initiated DSBs and/or activated the c-myc oncogene, we performed fluorescence in situ hybridization and c-myc Southern blot analysis. Fluorescence in situ hybridization analysis of tumor #57 with a probe that hybridizes to the 5 0 end of the Igl locus and a chromosome 16 paint indicated that the t(16;9) and t(11;16) chromosome 16 breakpoint occurred near or within Igl (Figure 3a) . Fluorescence in situ hybridization of tumors #99, 55, 603 and 972 using probes that hybridize centromeric of the C H genes or across the cmyc locus demonstrated that the t(12;15) translocations in these tumors juxtaposed Igh and c-myc (Figure 3b and data not shown). In addition, Fluorescence in situ hybridization analysis of tumor #29 using a probe that hybridizes centromeric of miR142 and a chromosome 15 paint indicated that miR142 was located at the t(11;15) breakpoint (Figure 3c ). None of these translocations involved c-myc amplification. The c-myc gene resides on an B20-kb EcoRI fragment (Figure 3d ) that can change size upon translocations involving c-myc. Southern blot analysis of EcoRI-digested DNA using a 3 0 c-myc probe revealed disruption of the c-myc locus on one allele in tumors #99 and #29 (Figure 3e ), providing evidence that the Igh and miR142 loci translocated into the 5 0 end of the c-myc locus in these tumors similar to the RAG/ AID-initiated translocations found in Burkitt's lymphoma (BL) and other human B lymphomas. Tumors #55, 99 and 603 with clonal Igh/c-myc translocations and tumor #29 with a clonal miR142/c-myc translocation contained Igk and Sm rearrangements (Figure 1e and data not shown), consistent with the notion that these oncogenic lesions formed because of 'off-target' AID activity (Robbiani et al., 2009 ). We were not able to generate metaphases from tumor #160; however, Southern analysis revealed substantial c-myc amplification (Figure 3e ), indicating that this pro-B lymphoma likely arose from a RAG-generated Igh/c-myc translocation with co-amplification of Igh and c-myc as occurs in NHEJ/Tp53-deficient and H2AX/Tp53-deficient mice . Metaphase spreads were prepared from tumors as described . Cytogenetic analyses were performed by manufacturer's instructions (Applied Spectral Imaging (ASI); Vista, CA, USA). Slides were examined under a BX61 microscope (magnification: Â 600) from Olympus (Center Valley, PA, USA), controlled by a LAMBDA 10-B Smart Shutter from Sutter Instrument (Novato, CA, USA). Images were captured using a LAMBDA LS light source from Sutter Instrument, and a COOL-1300QS camera ASI (ASI, Vista, CA, USA) then analyzed and managed through Case Data Manager Version 5.5 configured by ASI. (Zhu et al., 2002; Bassing et al., 2003; Celeste et al., 2003a; Gladdy et al., 2003; Rooney et al., 2004) . Tumor #61 contained a disrupted c-myc locus (Figure 3e ) but lacked translocations detectable by spectral karyotyping ( Table 1 ), suggesting that a genomic deletion involving the 5 0 end of the c-myc locus occurred on one allele. Collectively, these data indicate that cre-mediated Tp53 deletion initiating in pro-B cells leads to B lineage lymphomas with recurrent Igh/c-myc or other clonal translocations generated through aberrant V(D)J recombination, CSR, or possibly SHM.
The mb1-cre:Tp53 flox/flox cohort mice in this study developed B lymphoid tumors harboring clonal translocations at a similar rate as published Tp53 À/À cohort mice succumbed to thymic lymphomas with aneuploidy, but lacking genomic instability (Donehower et al., 1992; Jacks et al., 1994; Bassing et al., 2003; Celeste et al., 2003a) . This finding indicates that the development of aneuploid thymic lymphomas masks B lineage lymphomas in Tp53 À/À mice and/or the onset of B lymphoid tumors with clonal translocations is accelerated in mb1-cre:Tp53 flox/flox mice as compared with in Tp53 À/À mice. We recently showed that mice with cre-mediated deletion of H2ax and Tp53 initiating in thymocytes succumb to spontaneous thymic lymphomas at later ages than germline H2ax/Tp53-deficient mice (Yin et al., 2010) . In this context, oncogenic lesions that arise from stresses other than DSBs in Tp53 À/À cells before lymphocyte lineage commitment and/or in developing T lineage lymphocytes might drive thymocyte transformation more effectively than translocations that arise in B lineage cells. Although cre expression in cultured mouse embryonic cells causes genomic instability (Loonstra et al., 2001; Silver and Livingston, 2001) , constitutive cre expression initiating in thymocytes neither leads to a detectable increase in genomic instability nor accelerates the development of thymic lymphomas in Tp53 À/À mice (Cheung et al., 2002) . Still, it is possible that mb1-cre expression causes oncogenic translocations or other lesions that cooperate with RAG/AID-initiated translocations to accelerate the transformation of Tp53-deficient B lineage cells. Alternatively, Tp53 deletion in B lineage cells, theoretically, could preclude compensatory genetic and/or epigenetic changes associated with germline Tp53-deficiency.
Comparison of spontaneous lymphoma predisposition among Tp53
À/À and mb1-cre:Tp53 À/À mice with and without genetic or surgical ablation of thymocytes would be needed to distinguish among these possibilities. Regardless, as mb1-cre mice do not develop B flox/flox tumors and 129SvEv or C57BL6 kidneys, conducted as previously described Wu et al., 2003) . The position of the germline (GL) band is indicated. The images were cropped from a larger blot. lymphoid tumors, our data demonstrate unequivocally that Tp53 serves critical functions in B lineage cells to prevent transformation caused by Igh/c-myc or other oncogenic translocations in cell populations experiencing physiological levels of RAG/AID DSB intermediates.
B lineage lymphomas account for a significant percentage of human cancers. These malignancies frequently contain oncogenic IG translocations. Inactivating somatic mutations of TP53 correlate with IGH translocations in diffuse large B-cell lymphoma (DLBCL) and BL, as well as chemotherapy resistance, rapid disease progression and poor prognosis in patients with B lymphoid tumors (Kuppers, 2005; Cheung et al., 2009) . Our analysis of mb1-cre:Tp53 flox/flox mice provides evidence that the somatic TP53 mutations found in DLBCL and BL may contribute to the development of these malignancies. The molecular pathogenesis of human B lineage lymphomas with IG translocations remains largely unknown, which hinders the development of more effective and less toxic treatments. Thus, mb1-cre:Tp53 flox/flox mice may provide a useful preclinical model for conducting genome-wide screens to identify genetic/epigenetic changes that cooperate with TP53 inactivation and activation of C-MYC or other oncogenes to enable DLBCL and BL. This animal model also could be used to evaluate the potential efficacy of more specific and less toxic treatments for DLBCL and BL tumors with TP53 inactivation, such as inhibitors of CHK1 or p38 MAPK (Reinhardt et al., 2007; Fishler et al., 2010) . Finally, our results suggest that conditional Tp53 deletion in different lineages and developmental stages may provide the basis for pre-clinical models of other human hematopoietic malignancies that contain TP53 inactivation.
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